Caseware UK (AP4) 2024.0.164 2024.0.164 2024-09-302024-09-30No description of principal activityThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2023-10-01false43falsetruefalse 08019969 2023-10-01 2024-09-30 08019969 2022-10-01 2023-09-30 08019969 2024-09-30 08019969 2023-09-30 08019969 c:Director1 2023-10-01 2024-09-30 08019969 d:MotorVehicles 2023-10-01 2024-09-30 08019969 d:MotorVehicles 2024-09-30 08019969 d:MotorVehicles 2023-09-30 08019969 d:MotorVehicles d:OwnedOrFreeholdAssets 2023-10-01 2024-09-30 08019969 d:OfficeEquipment 2023-10-01 2024-09-30 08019969 d:OfficeEquipment 2024-09-30 08019969 d:OfficeEquipment 2023-09-30 08019969 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-10-01 2024-09-30 08019969 d:OwnedOrFreeholdAssets 2023-10-01 2024-09-30 08019969 d:CurrentFinancialInstruments 2024-09-30 08019969 d:CurrentFinancialInstruments 2023-09-30 08019969 d:CurrentFinancialInstruments d:WithinOneYear 2024-09-30 08019969 d:CurrentFinancialInstruments d:WithinOneYear 2023-09-30 08019969 d:ShareCapital 2024-09-30 08019969 d:ShareCapital 2023-09-30 08019969 d:RetainedEarningsAccumulatedLosses 2024-09-30 08019969 d:RetainedEarningsAccumulatedLosses 2023-09-30 08019969 d:AcceleratedTaxDepreciationDeferredTax 2024-09-30 08019969 d:AcceleratedTaxDepreciationDeferredTax 2023-09-30 08019969 c:FRS102 2023-10-01 2024-09-30 08019969 c:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 08019969 c:FullAccounts 2023-10-01 2024-09-30 08019969 c:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 08019969 2 2023-10-01 2024-09-30 08019969 e:PoundSterling 2023-10-01 2024-09-30 iso4217:GBP xbrli:pure

Registered number: 08019969









THAMES MEDICAL LECTURES LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 SEPTEMBER 2024

 
THAMES MEDICAL LECTURES LIMITED
 
 
  
ACCOUNTANTS' REPORT TO THE BOARD OF DIRECTORS ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF THAMES MEDICAL LECTURES LIMITED
FOR THE YEAR ENDED 30 SEPTEMBER 2024

You consider that the Company is exempt from an audit for the year ended 30 September 2024. You have acknowledged, on the Statement of financial position, your responsibilities for ensuring that the Company keeps adequate accounting records which comply with section 386 of the Companies Act 2006, and for preparing the financial statements which give a true and fair view of the state of affairs of the Company and of its profit or loss for the financial year.

In accordance with your instructions, we have prepared the financial statements on pages 9 from the accounting records of the Company and on the basis of information and explanations you have given to us.

We have not carried out an audit or any other review, and consequently we do not express any opinion on these financial statements.

  



Witton Metcalfe
 
London House
77 High Street
Sevenoaks
Kent
TN13 1LD
8 April 2025
Page 1

 
THAMES MEDICAL LECTURES LIMITED
REGISTERED NUMBER: 08019969

STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
39,667
45,289

  
39,667
45,289

Current assets
  

Debtors: amounts falling due within one year
 5 
765
5,063

Cash at bank and in hand
 6 
1,357,396
729,575

  
1,358,161
734,638

Creditors: amounts falling due within one year
 7 
(209,185)
(131,671)

Net current assets
  
 
 
1,148,976
 
 
602,967

Total assets less current liabilities
  
1,188,643
648,256

Provisions for liabilities
  

Deferred tax
  
(8,657)
-

  
 
 
(8,657)
 
 
-

Net assets
  
1,179,986
648,256


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
1,179,985
648,255

  
1,179,986
648,256


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on
Page 2

 
THAMES MEDICAL LECTURES LIMITED
REGISTERED NUMBER: 08019969
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 30 SEPTEMBER 2024

8 April 2025.




Philip David Benjamin
Director

The notes on pages 4 to 9 form part of these financial statements.

Page 3

 
THAMES MEDICAL LECTURES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

1.


General information

Thames Medical Lectures Limited is a private company limited by shares registered in England and Wales number 08019969, its registered office is situated at International House, 36-38 Cornhill, London, EC3V 3NG. Its principal activity is lecturing in joint venture with recognised educational establishments.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

Page 4

 
THAMES MEDICAL LECTURES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

2.Accounting policies (continued)

 
2.4

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
2.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Motor vehicles
-
20%
Office equipment
-
50%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 5

 
THAMES MEDICAL LECTURES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

2.Accounting policies (continued)

 
2.6

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.7

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.9

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.
Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

 
2.10

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 4 (2023 - 3).

Page 6

 
THAMES MEDICAL LECTURES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

4.


Tangible fixed assets





Motor vehicles
Office equipment
Total

£
£
£



Cost or valuation


At 1 October 2023
55,216
23,919
79,135


Additions
5,359
4,499
9,858



At 30 September 2024

60,575
28,418
88,993



Depreciation


At 1 October 2023
11,043
22,803
33,846


Charge for the year on owned assets
12,115
3,365
15,480



At 30 September 2024

23,158
26,168
49,326



Net book value



At 30 September 2024
37,417
2,250
39,667



At 30 September 2023
44,173
1,116
45,289


5.


Debtors

2024
2023
£
£


Amounts owed by joint ventures and associated undertakings
-
5,000

Prepayments and accrued income
765
63

765
5,063



6.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
1,357,396
729,575

1,357,396
729,575


Page 7

 
THAMES MEDICAL LECTURES LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
594
-

Corporation tax
196,210
121,912

Other creditors
2,143
1,712

Accruals and deferred income
10,238
8,047

209,185
131,671



8.


Deferred taxation




2024


£






Charged to profit or loss
(8,657)



At end of year
(8,657)

The deferred taxation balance is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(8,657)
-

(8,657)
-

Page 8
 


 
THAMES MEDICAL LECTURES LIMITED


 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024

9.


First time adoption of FRS 102

The policies applied under the entity's previous accounting framework are not materially different to FRS 102 and have not impacted on equity or profit or loss.

 
Page 9